# Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

> **NCT00792467** · PHASE1,PHASE2 · COMPLETED · sponsor: **Italfarmaco** · enrollment: 24 (actual)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **DRUG:** ITF2357

## Key facts

- **NCT ID:** NCT00792467
- **Lead sponsor:** Italfarmaco
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-07
- **Final completion:** 2010-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00792467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00792467, "Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00792467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*